NCT02820662

Brief Summary

The development of the retinal vascular network is generally complete during the 3rd trimester of pregnancy but may continue during the first 15 days of life. This late maturation may cause problems in pre-term births and may result in immature vascularization of the retina, a condition called retinopathy of prematurity. Among the different factors affecting the development of the retinal vasculature, the tissue level of omega-3 polyunsaturated fatty acids (PUFA) appears to be a crucial element, as does the form of the PUFA present in the tissues (nature of the phospholipids in their membranes). This project aims to show a possible association between levels of omega-3 PUFA and the onset of retinopathy of prematurity (ROP).

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P50-P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 30, 2015

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

June 29, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 1, 2016

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2018

Completed
Last Updated

February 6, 2026

Status Verified

February 1, 2026

Enrollment Period

2.8 years

First QC Date

June 29, 2016

Last Update Submit

February 4, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Stage of retinopathy of prematurity using a Retcam according to the ICROP classification (International Classification of Retinopathy of Prematurity) revised in 2005.

    At 4 weeks of life or 31 weeks of amenorrhea

Secondary Outcomes (1)

  • Concentrations of omega-3 PUFA in Red Blood Cell (RBC) membranes.

    At inclusion

Study Arms (1)

RETCAM

EXPERIMENTAL
Other: RETCAMBiological: Blood samples

Interventions

RETCAMOTHER
RETCAM
Blood samplesBIOLOGICAL
RETCAM

Eligibility Criteria

Age0 Months - 4 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Premature new-born infants born at less than 29 weeks of amenorrhea after informed consent has been obtained from a parent or the legal guardian of the infant

You may not qualify if:

  • Premature new-born infants presenting a life-threatening condition. Persons without national health insurance cover

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Universitaire

Dijon, 21079, France

Location

Related Publications (1)

  • Pallot C, Soudry Faure A, Charvy C, Ternoy N, Langlet Muteau C, Acar N, Bron AM, Speeg Schatz C, Creuzot-Garcher C. Screening for Retinopathy of Prematurity: Insight into Optimizing Screening. Ophthalmic Res. 2018;59(4):228-234. doi: 10.1159/000477622. Epub 2017 Jul 27.

MeSH Terms

Conditions

Retinopathy of Prematurity

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 29, 2016

First Posted

July 1, 2016

Study Start

July 30, 2015

Primary Completion

May 31, 2018

Last Updated

February 6, 2026

Record last verified: 2026-02

Locations